The Testicular Cancer Consortium (TECAC) is the only international collaborative group whose goal is to understand the genetic susceptibility to testicular germ cell tumors (TGCT). The incidence of TGCT is highest among men of European ancestry, and the most common cancer affecting men aged 15-45. TECAC and its members have conducted successful genome-wide association studies (GWAS) of TGCT; our latest analysis has identified 22 novel susceptibility alleles bringing the total validated risk markers to 68, accounting for 43% of heritability. Our studies have revealed the critical role of variation affecting essential pathways of male germ cell development and maturation, sex determination, chromosomal segregation, and DNA maintenance in TGCT susceptibility. We propose three complementary aims to deepen our discovery of inherited variation of susceptibility to TGCT, results of which will refine our understanding of the biology of TGCT and male germ cell development, provide insights into inherited variation predisposing to genomic instability, and improve our ability to identify patients at highest risk of disease.
In Aim 1, we will identify rare and common variants (individual and gene burden) using whole exome (WES) approaches followed by independent validation. We will conduct de novo WES on extant biosamples from 1000 and 1000 men with and without TGCT, respectively, and assemble existing WES data from 2066 men with TGCT from TECAC members for comparison to genomically matched (1:4) unaffected men from the Penn Medicine and UK Biobanks. To address data heterogeneity, WES data from all sources will be called together using a common pipeline. Fifty genes and 500 SNPs will be selected for validation in an independent set of extant biosamples from 5000 and 5000 men with and without TGCT, respectively, all with existing genome-wide genotyping.
In Aim 2, we will conduct a transcriptome-wide association study (TWAS), preceded by the largest GWAS study to date in 15,847 men with TGCT and 27,178 (230,610 with deCODE) men without TGCT. We will use a customized version of FUSION to perform the TWAS, annotated with expression data derived from TGCT cell lines, fetal and adult germ cells, GTEx, and single cell sequencing of germ cells.
In Aim 3, after in silico assessment and prioritization, 20 top loci/genes will be evaluated in TGCT in vitro models using siRNA and CRISPR to assess over-expression and knockdown effects on morphology, proliferation, chromosomal abnormalities, and cisplatin sensitivity. We will select candidate genes from our past genetic association efforts (11 preliminarily prioritized) and from novel loci/genes found in our WES (Aim 1), GWAS and TWAS (Aim 2) efforts. Our renewal builds upon our accomplishments and paves the way to identify novel susceptibility loci through three highly cohesive aims. Our findings will lead to further ground-breaking insights into the biology and genetic etiology of TGCT and will provide data needed to identify men at greatest need for surveillance, the optimal way to decrease serious TGCT treatment-related morbidity.

Public Health Relevance

Testicular germ cell tumors (TGCT) are the most common tumor type in white men ages 15-45, with an increasing incidence. They have a high heritability and inherited variation underlies ~50% of the risk of the disease. We build upon our prior research in the Testicular Cancer Consortium to identify additional genetic variation associated with disease risk, so that we expand our understanding of TGCT biology and epidemiology, as well as identify the men at highest risk of disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Cancer, Heart, and Sleep Epidemiology A Study Section (CHSA)
Program Officer
Zanetti, Krista A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Wang, Yanping; Gray, Dione R; Robbins, Alan K et al. (2018) Subphenotype meta-analysis of testicular cancer genome-wide association study data suggests a role for RBFOX family genes in cryptorchidism susceptibility. Hum Reprod 33:967-977
Wang, Zhaoming; McGlynn, Katherine A; Rajpert-De Meyts, Ewa et al. (2017) Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor. Nat Genet 49:1141-1147
Pyle, Louise C; Nathanson, Katherine L (2017) A practical guide for evaluating gonadal germ cell tumor predisposition in differences of sex development. Am J Med Genet C Semin Med Genet 175:304-314
Fang, Jun; Jia, Jinping; Makowski, Matthew et al. (2017) Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. Nat Commun 8:15034
Walsh, Michael F; Nathanson, Katherine L; Couch, Fergus J et al. (2016) Genomic Biomarkers for Breast Cancer Risk. Adv Exp Med Biol 882:1-32
Pyle, Louise C; Nathanson, Katherine L (2016) Genetic changes associated with testicular cancer susceptibility. Semin Oncol 43:575-581
Koster, Roelof; Mitra, Nandita; D'Andrea, Kurt et al. (2014) Pathway-based analysis of GWAs data identifies association of sex determination genes with susceptibility to testicular germ cell tumors. Hum Mol Genet 23:6061-8
Chien, Franklin L; Schwartz, Stephen M; Johnson, Rebecca H (2014) Increase in testicular germ cell tumor incidence among Hispanic adolescents and young adults in the United States. Cancer 120:2728-34
Couch, Fergus J; Nathanson, Katherine L; Offit, Kenneth (2014) Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 343:1466-70
Maxwell, Kara N; Nathanson, Katherine L (2013) Common breast cancer risk variants in the post-COGS era: a comprehensive review. Breast Cancer Res 15:212